Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

Plus Therapeutics emphasizes the recent NCCN update for CNS cancers, reinforcing cerebrospinal fluid analysis including the use of its CNSide assay platform in diagnosing and monitoring leptomeningeal metastases (LM). CNSide shows improved sensitivity over conventional cytology and is expanding U.S. commercial coverage. The company plans a rebrand …

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Kura Oncology announced that updated results from its FIT-001 Phase 1a study evaluating darlifarnib plus cabozantinib in cabozantinib-naïve advanced clear cell renal cell carcinoma (ccRCC) patients will be presented orally at the 2026 Kidney Cancer Research Summit. These long-term follow-up data continue to support darlifarnib's potential to enhanc…

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of AT-587, an oral antiviral nucleotide analog targeting Hepatitis E Virus (HEV), which currently has no approved treatments. The trial is a randomized, double-blind, placebo-controlled dose escalation study in healt…

USA Rare Earth Produces Commercial Grade Dysprosium Oxide and Neodymium-Praseodymium Oxide Samples from Recycled Magnet Material at Wheat Ridge Facility

USA Rare Earth Produces Commercial Grade Dysprosium Oxide and Neodymium-Praseodymium Oxide Samples from Recycled Magnet Material at Wheat Ridge Facility

USA Rare Earth announced successful production of commercial-grade dysprosium oxide and neodymium-praseodymium oxide samples from recycled rare earth magnet scrap at its Wheat Ridge, Colorado facility. This milestone positions the company among the few Western producers capable of heavy rare earth separation outside of Asia, enhancing its integrate…

Youxin Technology Announces a US$20 Million Strategic Investment Intent and Cooperation Framework with RiverBit

Youxin Technology Announces a US$20 Million Strategic Investment Intent and Cooperation Framework with RiverBit

Youxin Technology Ltd (Nasdaq: YAAS) announced a non-binding term sheet to invest up to $20 million in RiverBit Holding Limited, a company developing a decentralized perpetual contracts trading platform focused on tokenized U.S. equity perpetuals enabled with AI trading strategies. The investment is milestone-based, contingent on RiverBit reaching …

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

Pluri Inc.'s Chairman Alejandro Weinstein has increased his cumulative investment to over $17 million, now owning more than 30% of the company. This reflects his strong confidence in Pluri's advanced 3D cell expansion platform and the company's strategic shift toward commercial operations focused on longevity, tailored biologics, and regenerative m…

Octave to Report Second Quarter 2026 Financial Results on August 12

Octave to Report Second Quarter 2026 Financial Results on August 12

Octave Intelligence plc will report its second quarter 2026 financial results on August 12, 2026, before the U.S. market opens. The company will also hold a live conference call to discuss the results and business outlook. Octave provides software for mission-critical facilities and infrastructure, aiming to improve asset lifecycle performance and …

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Can-Fite BioPharma announced the granting of an Australian patent application titled "Treatment of Advanced Metastatic Cancer," further protecting its oncology drug Namodenoson. The drug is currently in pivotal Phase 3 trial for hepatocellular carcinoma and has completed Phase 2a trial in pancreatic cancer with plans for a Phase 2b study in combina…

Haoxi Health Technology Limited Announces Strategic Cooperation Framework with NOVA MEDIA to Develop An AI Digital Marketing System

Haoxi Health Technology Limited Announces Strategic Cooperation Framework with NOVA MEDIA to Develop An AI Digital Marketing System

Haoxi Health Technology has entered into a strategic cooperation framework agreement with NOVA MEDIA to develop an AI digital marketing system. This system will leverage generative AI and AI digital human technology to automate content creation and enhance marketing operations on Chinese digital platforms, aiming to improve efficiency and customer …

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Spero Therapeutics announced a $105 million non-recourse, non-dilutive royalty financing deal backed by future milestone and royalty payments from Utebzi sales. The funding supports the Phase 2 clinical development of SP001, an immunology-focused monoclonal antibody acquired from Innovent Biologics. The transaction extends Spero's cash runway into …

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics has entered into an exclusive license agreement with Innovent Biologics for SP001 (IBI355), a third-generation Fc-silent anti-CD40L antibody. Spero gains global rights excluding Greater China, where Innovent retains rights. The agreement includes milestone payments up to $1.1 billion plus royalties. Spero plans to begin a Phase 2…

Unity Bancorp Reports Quarterly Earnings of $14.5 Million

Unity Bancorp Reports Quarterly Earnings of $14.5 Million

Unity Bancorp, Inc. reported net income of $14.5 million for Q2 2026, showing slight growth from the previous quarter and year-over-year. The bank demonstrated healthy loan and deposit growth, strong capital levels, and a robust net interest margin. The CEO highlighted resilience in the New Jersey economy and emphasized continued customer activity …

KBR’s Mission Technology Solutions Selected for Multiple-Award Advisory Contract for National Air and Space Intelligence Center

KBR’s Mission Technology Solutions Selected for Multiple-Award Advisory Contract for National Air and Space Intelligence Center

KBR's Mission Technology Solutions division has been awarded a multiple-award IDIQ contract by the National Air and Space Intelligence Center valued up to $866 million over five years. The contract will have KBR provide advisory and technical support to advance intelligence systems for the U.S. Air Force and broader defense and intelligence communi…

Beam Global Announces Preliminary Second Quarter 2026 Revenue Up More Than 170% From Q1 And More Than 20% Year-Over-Year

Beam Global Announces Preliminary Second Quarter 2026 Revenue Up More Than 170% From Q1 And More Than 20% Year-Over-Year

Beam Global announced preliminary Q2 2026 revenue exceeding $8.5 million, representing a more than 170% increase from Q1 and over 20% year-over-year growth. Revenue growth was driven by diversification across multiple proprietary products and expanding international markets, including the Middle East and Europe. The company also highlighted operati…